InsiderSource
NTLA

Intellia Therapeutics, Inc.

SEC CIK 1652130
$12.11 −2.0% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
86
Most recent
Advertisement

At a glance

Insiders at NTLA have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Leonard John M sold $7.6M of NTLA, trimming their stake 6%.

Most active filer: Leonard John M, with 55 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for NTLA, newest first
View on SEC EDGAR ↗
NTLA
Intellia Therapeutics, Inc.
Sell Dube Michael P · VP, Chief Accounting Officer · Open-market sale · filed Oct 3, 2025 ΔOwn −3.3%

Dube Michael P sold $32.5K of NTLA, trimming their stake 3%.

−$32.5K
1,871 sh @ $17
NTLA
Intellia Therapeutics, Inc.
Buy CHASE WILLIAM J · Director · Open-market purchase · filed Aug 22, 2025 ΔOwn +288%

Chase William J, NTLA's Director, spent $1M of their own money on 100,000 shares at $10, growing their stake 288%.

+$1M
100,000 sh @ $10
NTLA
Intellia Therapeutics, Inc.
Sell Lebwohl David · EVP, Chief Medical Officer · Open-market sale · filed Jan 7, 2025 ΔOwn −9.8%

Lebwohl David sold $116.4K of NTLA, trimming their stake 10%.

−$116.4K
9,557 sh @ $12
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Jan 7, 2025 ΔOwn −2.8%

Leonard John M sold $326.5K of NTLA, trimming their stake 3%.

−$326.5K
26,807 sh @ $12
NTLA
Intellia Therapeutics, Inc.
Sell Verwiel Frank · Director · Open-market sale · filed Jun 20, 2024 ΔOwn −7.7%

Verwiel Frank sold $37.6K of NTLA, trimming their stake 8%.

−$37.6K
1,505 sh @ $25
Advertisement
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Jan 5, 2024 ΔOwn −2.2%

Leonard John M sold $566.3K of NTLA, trimming their stake 2%.

−$566.3K
19,223 sh @ $29
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Jan 6, 2023 ΔOwn −0.9%

Leonard John M sold $248.3K of NTLA, trimming their stake 1%.

−$248.3K
6,673 sh @ $37
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Sep 1, 2021 ΔOwn −5.9%

Leonard John M sold $7.6M of NTLA, trimming their stake 6%.

−$7.6M
44,735 sh @ $170
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Sep 1, 2021 ΔOwn −5.0%

Leonard John M sold $5.86M of NTLA, trimming their stake 5%.

−$5.86M
37,833 sh @ $155
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Sep 1, 2021 ΔOwn −1.0%

Leonard John M sold $1.15M of NTLA, trimming their stake 1%.

−$1.15M
7,428 sh @ $155
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Sep 1, 2021 ΔOwn −2.1%

Leonard John M sold $2.42M of NTLA, trimming their stake 2%.

−$2.42M
15,567 sh @ $156
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Sep 1, 2021 ΔOwn −0.7%

Leonard John M sold $746.8K of NTLA, trimming their stake 1%.

−$746.8K
4,758 sh @ $157
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Aug 25, 2021 ΔOwn −2.5%

Leonard John M sold $2.86M of NTLA, trimming their stake 3%.

−$2.86M
18,874 sh @ $152
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Aug 25, 2021 ΔOwn −1.1%

Leonard John M sold $1.25M of NTLA, trimming their stake 1%.

−$1.25M
8,165 sh @ $153
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Aug 20, 2021 ΔOwn −1.3%

Leonard John M sold $1.46M of NTLA, trimming their stake 1%.

−$1.46M
9,726 sh @ $150
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Aug 20, 2021 ΔOwn −1.0%

Leonard John M sold $1.06M of NTLA, trimming their stake 1%.

−$1.06M
6,993 sh @ $152
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Aug 20, 2021 ΔOwn −0.8%

Leonard John M sold $908.2K of NTLA, trimming their stake 1%.

−$908.2K
5,963 sh @ $152
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Apr 2, 2021 ΔOwn −3.4%

Leonard John M sold $2.04M of NTLA, trimming their stake 3%.

−$2.04M
24,314 sh @ $84
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Apr 2, 2021 ΔOwn −2.0%

Leonard John M sold $1.15M of NTLA, trimming their stake 2%.

−$1.15M
13,895 sh @ $83
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Feb 9, 2021 ΔOwn −4.1%

Leonard John M sold $2.1M of NTLA, trimming their stake 4%.

−$2.1M
28,043 sh @ $75
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Feb 9, 2021 ΔOwn −1.2%

Leonard John M sold $540.3K of NTLA, trimming their stake 1%.

−$540.3K
8,043 sh @ $67
NTLA
Intellia Therapeutics, Inc.
Sell LEONARD JOHN M · Director, President and CEO · Open-market sale · filed Feb 9, 2021 ΔOwn −2.2%

Leonard John M sold $951.3K of NTLA, trimming their stake 2%.

−$951.3K
14,018 sh @ $68
Advertisement

About NTLA insider activity

This page tracks every recent Form 4 filed for Intellia Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is NTLA insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Intellia Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.